人源化抗HER2单克隆抗体单药治疗HER2过表达、转移性疾病化疗后进展的转移性乳腺癌女性的多国疗效与安全性研究
这项多国研究纳入222例HER2过表达、转移性疾病化疗后进展的转移性乳腺癌女性,接受负荷剂量4 mg/kg静脉给药后每周2 mg/kg维持剂量的人源化抗HER2单克隆抗体单药治疗。独立盲法评估委员会确认客观缓解率为15%(95%CI 11%至21%),中位缓解持续时间9.1个月,中位生存期13个月。心脏功能障碍发生率为4.7%,仅1%患者因治疗相关不良事件终止研究。
要点
- 222例HER2过表达转移性乳腺癌患者接受抗HER2单克隆抗体单药治疗,客观缓解率15%。
- 中位缓解持续时间9.1个月,中位生存期13个月。
- 心脏功能障碍发生率4.7%,仅1%因治疗相关不良事件终止研究。
核心结论
- 重组人源化抗HER2单克隆抗体单药治疗可使HER2过表达、转移性疾病化疗后进展的转移性乳腺癌女性产生持久的客观缓解,且耐受性良好。
研究设计与样本
- 多国研究,纳入222例HER2过表达、转移性疾病化疗后进展的转移性乳腺癌女性,接受负荷剂量4 mg/kg静脉给药后每周2 mg/kg维持剂量的人源化抗HER2单克隆抗体单药治疗。
主要发现
- 独立盲法评估委员会确认8例完全缓解和26例部分缓解,意向治疗人群客观缓解率为15%(95%CI 11%至21%)。
- 中位缓解持续时间为9.1个月,中位生存期为13个月。
- 约40%患者发生输注相关发热和/或寒战,通常仅发生于首次输注,严重程度为轻至中度,经对乙酰氨基酚和/或苯海拉明治疗成功。
- 心脏功能障碍发生率为4.7%,仅1%患者因治疗相关不良事件终止研究。
- 化疗常见的不良反应如脱发、黏膜炎和中性粒细胞减少很少见。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evaluated in women with HER2-overexpressing metastatic breast cancer that had progressed after chemotherapy for metastatic disease. PATIENTS AND METHODS: Two hundred twenty-two women, with HER2-overexpressing metastatic breast cancer that had progressed after one or two chemotherapy regimens, were enrolled. Patients received a loading dose of 4 mg/kg intravenously, followed by a 2-mg/kg maintenance dose at weekly intervals. RESULTS: Study patients had advanced metastatic disease and had received extensive prior therapy. A blinded, independent response evaluation committee identified eight complete and 26 partial responses, for an objective response rate of 15% in the intent-to-treat population (95% confidence interval, 11% to 21%). The median duration of response was 9.1 months; the median duration of survival was 13 months. The most common adverse events, which occurred in approximately 40% of patients, were infusion-associated fever and/or chills that usually occurred only during the first infusion, and were of mild to moderate severity. These symptoms were treated successfully with acetaminophen and/or diphenhydramine. The most clinically significant adverse event was cardiac dysfunction, which occurred in 4.7% of patients. Only 1% of patients discontinued the study because of treatment-related adverse events. CONCLUSION: Recombinant humanized anti-HER2 monoclonal antibody, administered as a single agent, produces durable objective responses and is well tolerated by women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Side effects that are commonly observed with chemotherapy, such as alopecia, mucositis, and neutropenia, are rarely seen.
引用
- Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. J Clin Oncol. 2023. PMID: 36881998. doi:10.1200/JCO.22.02510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。